Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial

Neoadjuvant chemotherapy (NAC) remains an important therapeutic option for advanced oesophageal cancer (OC). Pathological tumour regression grade (TRG) may offer additional information by directing adjuvant treatment and/or follow‐up but its clinical value remains unclear. We analysed the prognostic value of TRG and associated pathological factors in OC patients enrolled in the Medical Research Council (MRC) OE02 trial.

[1]  R. Langer,et al.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy , 2018, Virchows Archiv.

[2]  B. O'neill,et al.  ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) , 2017, BMC Cancer.

[3]  E. Steyerberg,et al.  Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  R. van Hillegersberg,et al.  The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  S. Broderick,et al.  Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  H. Grabsch,et al.  Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Hölscher,et al.  Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer. , 2016, Seminars in thoracic and cardiovascular surgery.

[8]  T. Fujita,et al.  Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery , 2016, Journal of surgical oncology.

[9]  S. Broderick,et al.  Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer. , 2016, The Annals of thoracic surgery.

[10]  K. Haustermans,et al.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Peters,et al.  Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy. , 2015, The Annals of thoracic surgery.

[12]  R. Langer,et al.  Assessment of Tumor Regression of Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy: Comparison of 2 Commonly Used Scoring Approaches , 2014, The American journal of surgical pathology.

[13]  A. Bateman,et al.  Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. , 2013, World journal of gastroenterology.

[14]  R. Langer,et al.  Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant Treatment , 2013, Front. Oncol..

[15]  J. Luketich,et al.  Oesophageal carcinoma , 2013, The Lancet.

[16]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[17]  Lan-Jun Zhang,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[18]  A. Hölscher,et al.  Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. , 2011, The Annals of thoracic surgery.

[19]  Nilay Shah,et al.  Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer , 2010, Annals of Surgical Oncology.

[20]  W. Allum,et al.  Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Langer,et al.  Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas , 2009, Modern Pathology.

[22]  S. Baldus,et al.  Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification , 2005, Annals of surgery.

[23]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[24]  D. Girling.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.

[25]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.